Literature DB >> 7495702

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.

E A Lien1, G Anker, P M Ueland.   

Abstract

We measured the serum levels of tamoxifen and 5 of its metabolites in serum from 7 premenopausal and 9 postmenopausal women during the first 56 days of treatment. The serum levels of N-desdimethyltamoxifen were higher in postmenopausal women compared to premenopausal women (P < 0.02). A similar trend was observed for N-desmethyltamoxifen (P = 0.06).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495702     DOI: 10.1016/0960-0760(95)00169-z

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  5 in total

Review 1.  A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Authors:  Nahla E El-Ashmawy; Rania M Khalil
Journal:  Tumour Biol       Date:  2013-12-12

2.  Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

Authors:  Rob ter Heine; Lisette Binkhorst; Anne Joy M de Graan; Peter de Bruijn; Jos H Beijnen; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.

Authors:  Kristin Dickschen; Stefan Willmann; Kirstin Thelen; Jörg Lippert; Georg Hempel; Thomas Eissing
Journal:  Front Pharmacol       Date:  2012-05-21       Impact factor: 5.810

4.  Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.

Authors:  João Paulo Bianchi Ximenez; Jurandyr Moreira de Andrade; Maria Paula Marques; Eduardo Barbosa Coelho; Guilherme Suarez-Kurtz; Vera Lucia Lanchote
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-19       Impact factor: 2.483

5.  Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Authors:  Jennifer Gjerde; Sara Gandini; Aliana Guerrieri-Gonzaga; Line L Haugan Moi; Valentina Aristarco; Gunnar Mellgren; Andrea Decensi; Ernst A Lien
Journal:  Breast Cancer Res Treat       Date:  2012-05-05       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.